---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000120"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:14:57.060676+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Nurix to present updated Phase 1 NX-5948 data at investor meetings starting Sept 5

## Summary
- Company began investor roadshow on September 5, 2024, with an updated investor slide deck.
- Deck includes new data from the Phase 1 trial of NX-5948 for various B-cell malignancies.
- No specific numerical results (e.g., response rates, safety) are disclosed in this 8-K filing.
- NX-5948 is a targeted protein degrader; the full presentation may contain efficacy/safety details.

## SEC filing metadata
- accession: 0001549595-24-000120
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000120/0001549595-24-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000120/nrix-20240905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000120
- JSON: https://secwatch.observer/filing/0001549595-24-000120.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.